Loading clinical trials...

The Effect of AMG 133 on Gastric Emptying | Clinical Trials | Clareo Health

COMPLETEDPHASE1

The Effect of AMG 133 on Gastric Emptying

A Phase 1, Randomized, Double Blind, Multiple Dose, Placebo-controlled, Parallel Group Study to Evaluate the Impact of AMG 133 on Gastric Emptying in Participants Living With Overweight or Obesity

NCT07429032•Amgen

View on ClinicalTrials.gov

Summary

The primary objective of the trial is to evaluate the effect of AMG 133 versus placebo on acetaminophen pharmacokinetics (PK), a marker for gastric emptying, in participants living with overweight or obesity.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female participants between 18 and 65 years of age.
•a. Females must not be pregnant or lactating.
•Body mass index between ≥ 27 to \< 40 kg/m\^2.

Exclusion Criteria

•History or evidence of clinically significant disorder, condition, or disease not otherwise excluded that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
•History of or active diabetes or Hemoglobin A1C ≥ 6.5% (≥ 48 mmol/mol).
•History or evidence of endocrine disorder.
•History of acute or chronic pancreatitis within 1 year, or elevation in serum lipase/amylase (\> 2 x the upper limit of normal \[ULN\]), or fasting serum triglyceride level of \> 500 mg/dL.
•Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
•Uncontrolled thyroid disease.
•History of or current signs of gastroparesis.
•History or current signs or symptoms of cardiovascular disease.
•History suggestive of esophageal, gastric, or duodenal ulceration or bowel disease; or a history of gastrointestinal surgery other than uncomplicated appendectomy or hernia repair.
•History of gastrointestinal tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, gastric/jejunal tube feeds, or uncontrolled inflammatory gastrointestinal disease.
+10 more criteria

Locations (1)

Fortrea Clinical Research Unit - Daytona Beach

Daytona Beach, Florida, United States

Key Dates

Start Date

April 17, 2025

Primary Completion Date

November 26, 2025

Completion Date

November 26, 2025

Last Updated

February 24, 2026

Enrollment

ACTUAL participants

Conditions

Overweight or Obesity

Interventions

AMG 133

DRUG

Placebo

DRUG

Acetaminophen

DRUG

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

NCT07160400

Part A: Healthy Part B: Overweight or Obesity

View study

RECRUITINGPHASE1

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

NCT07150962

Overweight or Obesity

View study

RECRUITINGPHASE3

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

The Effect of AMG 133 on Gastric Emptying

Inclusion Criteria

Exclusion Criteria

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Weight Reduction in CLBP

A Study of BGM0504 Injection in Participants with Obesity or Overweight

Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss